边缘可切除胰腺癌新辅助治疗优化策略的研究进展

Progression of optimizing strategy of neoadjuvant therapy for borderline resectable pancreatic cancer

胰腺癌具有高度侵袭性,预后差,仅少数患者在确诊时存在手术根治机会。随着医学技术的发展,介于明确可切除与不可切除胰腺癌之间,划分出了一种特殊类型,即边缘可切除胰腺癌(BRPC)。此类胰腺癌根治性手术难度大,R0切除率低、复发风险高,新辅助治疗在提高BRPC的R0切除率和延长生存期上发挥了重要的作用。如何优化新辅助治疗策略、改善BRPC患者的预后值得临床重视。

Pancreatic cancer is considered as one of the most aggressive malignancies with poor prognosis. Only a few newly diagnosed patients are possible candidates for curative resection. With the development of medical technology, there is a new subtype of pancreatic cancer called borderline resectable pancreatic cancer （BRPC） that has been distinguished from reseetable and unresectable cases. BRPC has low Ro resection rate and high risk of recurrence. Neoadjuvant therapy is playing an important role in BRPC aiming to improve the R0 resection rate and prolong survival. How to optimize neoadjuvant therapy strategy and improve prognosis of BRPC is worth of attention.